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Abstract 
RNAi has always captivated scientists due to its tremendous power to modulate the phenotype of 
living organisms. This natural and powerful biological mechanism can now be harnessed to down-
regulate specific gene expression in diseased cells; opening up endless opportunities. Since most of 
the conventional siRNA delivery methods are limited by a narrow therapeutic index and significant 
side and off-target effects, we are now in the dawn of a new age in gene therapy driven by 
nanotechnology vehicles for RNAi therapeutics. Here, we outlook the “do’s and dont’s” of the 
*Manuscript
Click here to view linked References
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inorganic RNAi nanomaterials developed in the last 15 years and the different strategies employed are 
compared and scrutinized, offering important suggestions for the next 15. 
 
1. Introduction  
During the last 15 years we assisted to a fast and significant revolution in the RNA world. One of the 
most astonishing milestones was the discovery of RNA interference (RNAi), a regulatory mechanism 
of gene expression widely diffused in eukaryotes, including fungi, plants, and animals. Overall, based 
on noncoding double-stranded RNA (dsRNA) molecules, RNAi drives homology-dependent 
degradation of target mRNA leading to specific gene silencing [1]. The discovery of RNAi has 
expanded our knowledge of gene regulation since Fire, Mello and colleagues demonstrated that long 
dsRNA mixtures were 10-100 fold more efficient at triggering gene silencing than single strand RNAs 
in Caenorhabditis elegans. However, the use of RNAi as a potent tool for gene regulation came when 
Elbashir and co-workers proved that synthetic small interfering RNAs (siRNAs) enabled sequence 
specific gene knockdown in a mammalian cell line [2]. These observations laid the foundations to 
employ RNAi as a key tool for gene functional analysis as well as a therapeutic tool 
So far, four major types of noncoding RNAs have been identified as RNAi effectors: siRNAs, 
microRNAs (miRNAs), piwi-interacting RNAs (piRNAs) and long intervening noncoding RNAs 
(lincRNAs) [3]. While the main goal of piRNA goes from transcriptional gene silencing and genome 
defence to transgenerational epigenetic mechanisms [4], miRNA and siRNA act more specifically as 
triggering molecules of gene silencing. Specifically, miRNAs are a large class of endogenous small 
regulatory molecules, derived from imperfectly paired hairpin RNA structures naturally encoded in 
the genome [5]. They prevalently act to control translational repression or mRNA degradation. 
Instead, siRNAs represent a heterogeneous class of noncoding RNAs typically including exogenous 
synthetic or viral inducers of RNAi (Figure 1). Despite their different biogenesis, miRNA and siRNA 
once into the cytoplasm share common molecular machineries as Dicer enzymes for precursors 
excision, and Ago proteins, which vehicle their silencing functions [6,7]. Consequently, the enzymes 
Dicer and Ago, together with the 21-23 nt duplex-derived RNAs represent the key components of the 
RNA silencing pathway.  
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Figure 1. The RNA interference pathway begins with long dsRNA precursors that are processed to siRNA 
duplexes by the RNase-III-like enzyme Dicer. These short dsRNAs are subsequently unwound and assembled 
into an effector complex, RNA Induced Silencing Complex (RISC), which can direct RNA cleavage, mediate 
translational repression or induce chromatin modification. The antisense strand then binds to its 
complementary/target mRNA. The strand antisense to the targeted mRNA is often referred to as the guide 
strand, and its base-paired sense strand is known as the passenger strand, which is destroyed upon incorporation 
of the guide strand into RISC. The catalytic RISC recognizes mRNAs containing perfect or near-perfect 
complementary sequence to the guide siRNA and cleaves the mRNAs at a site precisely 10 nucleotides from 
the 5’-end of the guide strand. Finally, mRNA degradation is achieved by endo- and exonucleases, resulting in 
knockdown of the expression of the corresponding genes. 
 
 
For a long time, RNAi has been considered a regulatory mechanisms merely controlling gene 
expression at the post-transcriptional level. Recent findings have now established that RNAi also 
plays a central role in transcriptional repression (RNA-induced transcriptional silencing, RITS). 
Nevertheless, a growing body of evidence supports RNAi regulating transcription through interactions 
with the transcriptional machinery. In light of this paramount potential, RNAi approaches are 
tremendously appealing for developing new therapies [8]. In fact, it has been shown that many human 
developmental and degenerative disorders as well as cancers encompass some form of aberrant gene 
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regulation. One of the first clinical approaches aiming to harness the RNAi pathway for gene silencing 
employed siRNA by intravenous administration in patients with age-related macular degeneration 
(AMD) to downregulate the vascular endothelial growth factor transcript [9]. Beside this and other 
ocular diseases, ongoing clinical trials using RNAi-based strategies hold promise for treating fatal 
disorders (viral infections, neurodegenerative diseases, inflammatory diseases, cancer) [9,10] or 
provide alternatives to traditional small molecule therapies [11-13]. However, several hurdles must be 
overcome before RNAi technology can be translated from an effective research tool into a feasible 
clinical practice. In this respect, one of the primary obstacles remains the efficient in vivo delivery of 
these small molecules to the target cell type. Depending on the mode of administration, siRNA must 
cross many biological barriers before reaching the target cells, facing degradation by nucleases, issues 
related to their relative instability and half-life, short-lived nature of their transient gene silencing, 
sequestration by the immune system and elicitation of an immune response [14]. Upon reaching the 
targeted cells, siRNA molecules cannot readily diffuse across cellular membranes due to their anionic 
backbone and hydrophilic nature. Thus, delivery vehicles must be used to protect/conceal the siRNA 
within biological fluids, while facilitating its transfection to the cytoplasm of the target cells. The 
different strategies developed for efficient siRNA delivery can be grouped in two categories: those 
involving a chemical modification of the siRNA and those mediating the delivery by exogenous 
compounds, such as aptamers, liposomes, nanoparticles (NPs), polymers, dendrimers, all requiring a 
specific chemistry to preserve the biological activity of the siRNA upon conjugation. In fact, the 
therapeutic efficiency of delivery vehicles and a specific siRNA can be increased by modifications in 
key characteristics such as charge, size, shape, composition, surface chemistry and targeting motifs. 
DNA/RNA nanomaterials have also been developed in the last year for miRNA sensing and delivery 
[15]. Probably those relying on nanoparticles hold the best promise to improving stability, cell 
penetration, increasing administration dose, while enabling the specificity and/or self-tracking 
properties (via conjugation to antibodies and/or fluorophores) or other nanoparticle dependent 
properties (magnetic, electric, optical properties). Among the numerous nanoparticle formulations 
employed for siRNA delivery, here we will focus on inorganic nanoparticles [16], i.e. nanosized 
structures made by an inorganic material (e.g. silica, gold, iron oxide, quantum dots, carbon 
nanotubes, calcium phosphate), coated by polymeric layers and conjugated to siRNA through specific 
approaches including covalent binding, electrostatic absorption and encapsulation, depending on the 
material [17-22]. Compared to conventional transfection agents, nanoparticle-conjugated siRNAs 
have been shown to be less susceptible to degradation by nuclease activity, exhibit greater cellular 
uptake and higher siRNA effective concentration; which has accelerated siRNA delivery in this 
direction over the past few years. 
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Table 1 depicts examples of nanoparticle formulations successfully employed to induce RNAi in vitro 
and in some case also in vivo. The material core dictates the strategy of siRNA conjugation, so that the 
absorption method is generally employed for mesoporous silica NPs (MSNs) and nanostructures made 
positively charged by chemical engineering, while covalent binding is the preferred approach for NP 
surfaces coated by reactive groups. The latter ensures more effective delivery of siRNA into the cell 
cytoplasm, avoiding undesired cargo release in biological fluids external to the target cells and thus 
decreasing RNAi efficacy. The strong thiol-gold interaction has been used extensively to decorate 
gold nanoparticles with thiol-derivatized oligonucleotides, while more sophisticated methods 
(including the siRNA conjugation to polymers coating the NP, i.e. Polyethylene glycol (PEG), 
Polyethylenimine (PEI)) have been developed more recently. These strategies have been implemented 
with others to graft other reactive groups onto the NP, allowing for further conjugation with multiple 
bioactive molecules, such as peptides to enhance cell penetration, fluorophores for imaging, and 
antibodies for specific cell targeting (see Table 1).  
 
Table 1. Examples of nanoparticle-based siRNA delivery systems. 
Nanoparticle type 
Conjugation 
type 
Target gene Biological system 
Efficiency of silencing/ 
detection method 
Ref 
Magnetic  NP 
Covalent binding 
GFP/RFP/ 
survivin 
9LGliosarcoma 
cells 
mouse 
50% -fluorescence intensity 
>80% -qRT-PCR 
[18] 
Absorption via 
lipids 
luciferase HeLa cells 90% - enzymatic activity [23] 
Magnetic 
nanobeads 
Surface 
absorption 
GFP HeLa cells n.d. -fluorescence intensity [22] 
Gold NP 
Gold-thiol 
conjugation 
luciferase HeLa cells > 70% -enzymatic activity [24] 
Gold-thiol 
conjugation 
luciferase HeLa cells > 90% -enzymatic activity [25] 
Covalent binding c-Myc 
HeLa cells 
Hydra 
mouse 
80% -enzymatic activity 
80% -qRT-PCR 
70% -qRT-PCR 
[26-28] 
Ionic interaction Lamin A/C HeLa cells 80% -immunoblot [29] 
Gold-thiol 
conjugation 
c-Myc 
LA4-cells 
mouse 
80% -qRT-PCR 
80-90% -bioluminescence 
imaging 
[27] 
Ciclodextrin/ 
adamantin 
interaction 
RRM2 human 
30-70% -qRT-PCR, 
immunolocalization 
[30] 
Mesoporous silica 
NP 
Pore/surface 
adsorption 
GFP/VEGF 
HeLa cells 
MDA-MB-231 
cells 
mouse 
80% -fluorescence intensity 
60% -RT-PCR 
80% -fluorescence intensity 
RT-PCR 
[31] 
Mesoporous silica  
NP  
(+doxorubicin) 
Adsorption 
Pgp (ABC drug 
efflux 
transporter) 
MCF-7 cells 
mouse 
50% - immunoblot 
10-90% -tumour weight, 
immunoblot, qRT-PCR 
[32] 
Gold nanorods-
mesoporous silica 
Covalent binding GFP HeLa cells 
60% -fluorescence intensity 
 
[33] 
Calcium Encapsulation luciferase H460 cells 50% enzymatic activity [20] 
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Despite the enormous efforts to develop NP based siRNA carriers, most of the studies have been 
performed in cell cultures, using reporter genes such as the green fluorescent protein or luciferase, 
allowing easy recording of the RNAi efficacy. Less abundant are studies employing pre-clinical 
animal models (mainly mouse) [18,28,31], or targeting biologically relevant genes, and very rare 
those reporting on clinical trials using inorganic nanoparticles [30,35]. In fact, there are no active 
clinical trials reporting the use of inorganic NPs to target any gene using siRNA delivery (see Table 
2).   
 
Table 2. Inorganic nanoparticles in clinical trials. 
Delivery vehicle 
Target 
gene 
Disease Phase Status ClinicalTrials.gov ID 
Gold + Iron 
Oxide-Silica  
NA 
Coronary Artery Disease 
Atherosclerosis 
1 Completed NCT01436123 
Gold + silica NA 
Stable Angina 
Heart Failure 
Atherosclerosis 
Multivessel Coronary Artery Disease 
1 
2 
Completed NCT01270139 
Gold NA Stomach Diseases 0 Recruiting NCT01420588 
Silica NA 
Head and Neck Cancer 
Melanoma 
Prostate Cancer 
Cervical Cancer 
Uterine Cancer 
0 Recruiting NCT02106598 
Iron oxide 
(magnetic) 
NA Head and Neck Cancer 0 Recruiting NCT01895829 
NA Leukemia - Completed NCT01411904 
NA Brain Neoplasms 1 Completed NCT00769093 
NA Multiple Sclerosis 0 Recruiting NCT01973517 
NA 
Papillary Carcinoma of Thyroid 
Metastatic to Regional Lymph Node 
Metastatic Medullary Thyroid Cancer 
Follicular Thyroid Cancer Lymph Node 
Metastasis 
0 Recruiting NCT01927887 
NA Cancer of Lymph Node 0 Recruiting NCT01815333 
NA 
Myocardial Infarction 
Inflammation 
2 Recruiting NCT01995799 
NA Pancreatic Cancer 4 Recruiting NCT00920023 
NA 
Bladder Cancer 
Genitourinary Cancer 
Prostate Cancer 
- Completed NCT00147238 
NA Myocardial Infarction - Completed NCT01323296 
NA 
Myocardial Infarction 
Inflammation 
- - NCT01127113 
NA Renal Transplant Rejection - Recruiting NCT02006108 
Phosphate  NP mouse 50% enzymatic activity 
Quantum dots Adsorption 
BACE1  
(b-secretase) 
SK-N-SH cells 50% -immunoblot [34] 
Single walled 
carbon nanotubes 
Covalent binding 
CXCR4  
(cell surface 
co-receptor) 
CD4 
T cells 
peripheral blood 
mononuclear cells 
50%-90% qRT-PCR 
60% qRT-PCR 
[17] 
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NA: not applicable  
 
From all the RNAi-based drugs in clinical trials, approximately 52% are lipid-based and polymeric 
NPs (organic NPs), 36% are naked siRNAs and 12% are bacteria/viral vectors [14] (see Table 3). 
Although necessary for a preliminary evaluation of the NP-based siRNA vehicles, in vitro studies do 
not mirror the complexities of the same cells within a physiological context, such as a whole animal; 
and many obstacles may arise in vivo, such as administration route, stability in blood, lymphatic 
systems and extracellular matrix, impacting on the RNAi efficiency. As such, in vivo evaluation of 
functional NPs using model organisms must be a priority to allow fast, cost and time saving 
screenings of intermediate and final abducts, before clinical trials are initiated [35].  
 
Table 3. RNAi-based drugs in clinical trials. Adapted from [14]. 
Delivery 
vehicle 
Target gene Disease Phase Status 
ClinicalTrials.gov 
ID 
lipid-based 
c-Myc Hepatocellular Carcinoma 
1 
2 
Recruiting NCT02314052 
c-Myc 
Solid Tumours 
Multiple Myeloma 
Non-Hodgkins Lymphoma 
1 Recruiting NCT02110563 
HSP47 
Moderate to Extensive Hepatic 
Fibrosis 
1 Recruiting NCT02227459 
PLK1 
Colorectal, Pancreas, Gastric, 
Breast and Ovarian Cancers With 
Hepatic Metastases 
1 Completed NCT01437007 
EphA2 Advanced Cancers 1 
Not yet 
recruiting 
NCT01591356 
ApoB Hypercholesterolaemia 1 Completed NCT00927459 
VP24, VP35, 
Zaire Ebola 
L-polymerase 
Ebola-virus infection 1 Recruiting NCT01518881 
KSP, VEGF Solid tumours 1 Completed NCT01158079 
TTR 
Transthyretin-mediated 
amyloidosis 
2 Recruiting NCT01617967 
naked siRNAs 
K6a (N171K 
mutation) 
Pachyonychia congenita 1 Completed NCT00716014 
VEGFR1 
Age-related macular degeneration, 
choroidal neovascularization 
2 Completed NCT00395057 
CASP2 
Optic atrophy, non-arteritic 
anterior ischaemic optic 
neuropathy 
1 Completed NCT01064505 
P53 Kidney injury, acute renal failure 1 Completed NCT00554359 
RTP801 
Choroidal neovascularization, 
diabetic retinopathy, diabetic 
macular edema 
2 Completed NCT01445899 
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RSV 
nucleocapsid 
Respiratory syncytial virus 
infections 
2 Completed NCT00658086 
bacteria/viral 
vectors 
Conserved 
regions of HBV 
HBV (human hepatitis B virus) 1 Recruiting NCT01872065 
CTNNB1 Familial adenomatous polyposis 
1 
2 
Recruiting - 
 
 
 
Only the continuous discussions and knowledge’s exchange between different disciplines may lay the 
foundations of an interdisciplinary platform for the smart design, testing and safe assessment of novel 
nanoconjugates for medical application. With this aim our consortium, in the frame of an European 
project (European Consortium NANOTRUCK, ERANET – NanoSciera+), adopted a hierarchical 
strategy to test siRNA functionalized gold nanoparticles, using biological systems of increasing 
complexity, ranging from cells, diblastic animal (the freshwater polyp, Hydra vulgaris) to mouse. By 
targeting the c-Myc protooncogene, and using both ionic and covalent approaches to conjugate siRNA 
to gold NP four potentially active siRNA-NP conjugates, from a total of eighteen compounds, were 
selected via evaluation using cell lines, which were tested in Hydra. In this more complex model two 
compounds were found to induce 80% c-Myc silencing; these were subsequently tested in a mouse 
model, where a single dose showed to be highly efficient in inducing c-Myc gene silencing [27,28]. 
Thus, our strategy not only reduced vertebrate experimentation, but also showed the broad 
functionality of the novel nanoconjugate across evolutionary distant species, suggesting universal 
rules underlying RNAi and nanoparticle/cell interaction. 
In recent years, inorganic nanoparticles have been gaining momentum as robust and effective 
nanodelivery alternative to organic NP for the effective delivery of therapeutic siRNA owing to their 
inherent properties, chemical stability and physical constancy, high purity via reproducible synthetic 
protocols allowing for adjustable size and morphology control, ease of surface modification for 
improved siRNA binding and targeted delivery. These inorganic nanoformulations present several 
advantages for cell targeting and selective delivery of siRNA that are now coming of age and 
translating to the clinics. This strenuous evolution shall be discussed in the present review. In 
addition, in this review we examined in detail the synthetic approaches for the effective conjugation of 
the nanoparticles and the siRNA. We also reviewed the most common approaches to assess gene 
silencing in vitro and in vivo. Finally we envisioned the upcoming perspectives of nanoparticle-
mediated gene silencing in nanomedicine. 
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2. Inorganic nanoparticles as siRNA carriers 
Since the first publication on RNA interference in 1998 [1], several RNAi-based therapeutic 
approaches have been proposed for promising clinical applications. Although this seems easy, the 
complexity of siRNA transfection is challenging once these biomolecules are too large and too 
hydrophilic to cross the cell membrane without the help of a transfection agent. Nanotechnology 
offers versatile targeted delivery platforms for RNAi therapeutics [36,37]. In the last 15 years the use 
of inorganic nanoparticles (gold, magnetic, silica and quantum dots) as siRNAs delivery agents has 
been investigated and extensively described. A milestone timeline of the last 15 years summarizing 
the greatest events in RNAi discovery and RNAi nanomaterials development is depicted in Figure 2. 
 
 
Figure 2. Milestone timeline of the last 15 years summarizing the greatest events in RNAi discovery (in blue) 
and RNAi inorganic (gold, silica, magnetic and quantum dot) nanoparticles development (in red). 
 
 
2.1. siRNA-Gold Nanoparticles 
In 2006, the first application of siRNA-gold nanoparticles (AuNPs) reported the use of 15 nm-AuNPs 
with thiolated PEG–PAMA and siRNA capable of silencing 65% of a reporter gene (luciferase) in 
human hepatocarcinoma cells [38]. Later, Mirkin and co-workers reported polyvalent siRNA-AuNP 
conjugates could be readily taken up by cells and that the particle bound siRNA could effectively 
regulate genes in the context of RNA interference [24]. In this system, PEG is significantly smaller 
than the siRNA in order to fully expose the siRNA on the particle surface presented to the cells. 
AuNPs modified with the hydrophilic PEG polymer, siRNAs and then coated with poly(β-
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aminoester)s have been shown to facilitate high levels of in vitro siRNA delivery and gene silencing 
in human cell lines [25]. Also, Braun et al. developed a laser-activated Au-nanoshell functionalized 
with TAT-lipid layer for transfection and selective siRNA delivery [39]. The authors reported that the 
TAT-lipid coating was able to efficiently mediate the cellular uptake of the nanoformulations and 
siRNA release occurred as a response to proficient and time dependent near-infrared (NIR) laser 
pulses.  
Recently, Conde et al. developed a theranostic system capable of intersecting all RNA pathways: from 
gene specific downregulation to silencing the silencers, i.e. siRNA and miRNA pathways. In fact, the 
only study reported so far concerning the use of AuNPs for the detection in living cells at the same 
time as oncomiR inhibition occurs was reported by Conde et al. The authors reported the development 
AuNPs functionalized with a fluorophore labelled hairpin-DNA, i.e. Gold nanobeacons, capable of 
efficiently silencing single gene expression, exogenous siRNA and endogenous miRNAs while 
yielding a quantifiable fluorescence signal directly proportional to the level of silencing [40-43] 
(Figure 3).  
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Figure 3. “Silencing the Silencers” with Gold Nanobeacons. (A-B) Human cells efficiently transfected with 
EGFP vector are tested for the blockage/recovery of gene expression mediated by a nanoparticle delivery 
technology. Gold nanoparticles functionalize with hairpin DNA (Au-nanobeacons) act as both promoters of 
gene silencing from an antisense (A) and RNA interference (B) approaches and as supporters for the recovery 
of gene expression. In the antisense approach (A), the EGFP silencing occur via gold nanobeacons-Antisense 
and the recovery of the EGFP expression by the action of small ssRNA oligos that block gold nanobeacons-
Antisense. In the RNA interference pathway (B), siRNAs for the silencing of EGFP expression and a gold 
nanobeacon Anti-siRNA were used to successfully blocking the antisense strand of siRNA molecules and the 
repression of gene silencing. (C) Blocking the microRNA pathway via a gold nanobeacon Anti-miRNA 
complementary to a specific microRNA involved in cancer progression, for example. Reproduced with 
permission [40]. Copyright 2015, Nature Publishing Group. 
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Several other studies using engineered NPs modified with siRNA have demonstrated a cytoplasmic 
delivery system of siRNA and efficient gene silencing using AuNPs. These include AuNPs 
functionalized with PEG or PEI polymers, cationic biodegradable polymers poly(β -aminoester) 
(PBAEs), cationic lipid bilayer coated AuNPs [29,44-46]. However, almost all nanoconjugates using 
siRNA have exclusively been tested in cell cultures and targeting only reporter genes (i.e. GFP or 
luciferase). 
As mentioned earlier, we provided evidence of in vitro and in vivo RNAi via the synthesis of a library 
of multifunctional AuNPs, using a hierarchical approach including three biological systems of 
increasing complexity: in vitro cultured human cells, in vivo freshwater polyp (Hydra vulgaris), and in 
vivo mice model [27,28] (Figure 4). We developed effective conjugation strategies to combine, in a 
highly controlled way, specific biomolecules to the surface of AuNPs such as: (a) biofunctional 
spacers; (b) cell penetrating peptides: membrane translocating agents (cell penetrating peptides, CPPs) 
that exploit more than one mechanism of endocytosis to overcome the lipophilic barrier of the cellular 
membranes and deliver large molecules and even small particles inside the cell; (c) siRNA 
complementary to a master regulator gene. As spacer, poly(ethylene glycol) (PEG) spacers, with a 
thiol end to bond covalently to the gold nanoparticle and carboxilic acid (thiol-PEG-COOH) and azide 
(thiol-PEG-N3) functional groups in the other end were used to increase solubility and 
biocompatibility. AuNPs functionalized with CPPs, such as TAT and RGD peptides, were used to 
better reach the cell cytoplasm and evade retention in sub-cellular organelles. As proof-of-concept, the 
protooncogene c-Myc was targeted, and the siRNA was bond covalently (thiol-siRNA) and ionically 
(naked siRNA) to AuNPs and the effect compared [28]. The differences between the ionic and 
covalent approach for the siRNA binding are further discussed in detailed (see Section 3).  
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Figure 4. Regulation of gene expression via multifunctional siRNA-gold nanoparticles. (1) The 
“NanoVehicles”: Covalent approach: the use of thiolated siRNA for the binding to the nanoparticle through the 
strong interaction gold-thiol; Ionic approach: binding of the negatively charged siRNA through ionic 
interactions to the modified surface of gold nanoparticle. (2) The “Hosts”: The nanoparticles were tested in a 
cancer cell line (HeLa) and in two animal models: Hydra vulgaris and C57BL/6j mice. (A,B) TEM images of 
lung epithelial cells. Mice were treated with NPcov@RGD@myc-siRNA by intratracheal instillation. At 4 
hours (A) after instillation, NPs are located in ruffles of lung epithelial cell membranes and a few NPs are in the 
vesicles. At 18 hours (B), huge amounts of NPs are found in vesicles or free in cytoplasm (scale bars 500 nm). 
(C,D) c-myc protein expression on alveolar epithelial cells in lung tissue after 48 hours treatment. (C) Mice 
instillated with NP-cov@RGD, (D) mice instillated with NP-cov@RGD@myc-siRNA. The c-MYC protein 
was detected by Alexa-488-conjugated anti-c-MYC antibody (green), and cell nuclei were DAPI stained (blue). 
Scale bars 200 μm. (E) Molecular assessment of RNAi efficiency in mice. The c-Myc expression levels were 
determined using β-actin as reference gene. Data marked with asterisks are statistically significant relative to 
the corresponding NP-ion/cov without siRNA (*, P ≤0.001; **, P ≤0.01). Reproduced and adapted with 
permission [28]. Copyright 2015, American Chemical Society. 
 
 
In addition to mediating RNAi, siRNA molecules have also the potential to potently induce the innate 
immune system, which constitutes an important challenge - the differentiation between therapeutic 
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effects caused by target-specific, RNAi-mediated gene silencing and those caused by nonspecific 
stimulation (i.e. inflammation/toxicity) of the innate immune system [47]. Further work has been 
reported on the innate immune response (as measured by interferon-β levels) to densely functionalized 
siRNA-AuNP to be significantly less (up to a 25-fold decrease) when compared to a lipoplex carrying 
the same DNA sequence. The authors proposed that the enzymes involved in recognizing foreign 
nucleic acids and triggering the immune response are impeded due to the local surface environment of 
the particle, in particular high charge density [48]. 
 
 
2.2. Magnetic Nanoparticles for RNAi 
Magnetic nanoparticles (MNPs) have emerged as nanotheranostics systems for gene silencing, tumour 
targeting/imaging and drug delivery [49]. MNPs have been frequently exploited as platforms for 
tracking the delivery of siRNA, as they can be used to image biodistribution by magnetic resonance 
imaging (MRI). Thus far, the most promising application of in vivo tumour therapy using MNPs has 
been reported by Namiki and co-workers [50]. The authors reported a new nanoformulation based on 
an oleic acid-coated magnetic nanocrystal core and a cationic lipid shell (Figure 5). This smart system 
can be magnetically guided to deliver and silence genes in vitro and in mice bearing gastric tumours. 
After systemically injecting the nanoformulation to tumour and applying a magnetic field, a 50% 
reduction in tumour mass was achieved.  
Another study reporting the use of MNPs as tools for magnetofection [51] and consequently for the 
enhancement of siRNA delivery using external magnetic fields have also been widely described 
[23,52-55]. 
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Figure 5. A novel magnetic crystal–lipid nanostructure for magnetically guided in vivo gene delivery. 
Schematic showing the preparation (upper) and assembly (middle) of LipoMag and reverse-phase evaporated 
magnetic liposomes (lower). Oleic acid-coated magnetic nanocrystal cores and the lipid shells form through 
hydrophobic interactions. Reproduced with permission [50]. Copyright 2015, Nature Publishing Group. 
 
 
Superparamagnetic iron oxide nanoparticles (SPIONs) are another example of siRNA-magnetic 
carriers, which are also widely studied MR contrast agents useful in both imaging and drug delivery 
applications [56-58]. The large surface area of SPIONs makes them perfect candidates for functional 
modification, enabling the conjugation of targeting molecules, drugs, and imaging contrasts agents. 
For instance, Kumar et al. synthesized multifunctional MNPs by attaching a near-infrared (NIR) 
optical dye Cy5.5 and a peptide that targets the tumour specific antigen mucin-1 to cross-linked 
dextran coated SPIONs [59]. The authors tested this tumour-targeted nanodrug to specifically shuttle 
siRNA to human breast tumours. Following delivery into subcutaneous mouse models of breast 
cancer, the nanodrug showed preferential tumour uptake that could be visualized by MRI and NIR 
optical imaging (NIRF). Medarova et al. also reported an important study using a magnetic 
nanoparticles labelled with a NIR dye and covalently linked to siRNA molecules to use as dual-
purpose probes for in vivo siRNA transfection and the simultaneous imaging of its accumulation in 
tumours by high-resolution MRI and in vivo NIRF (Figure 6). This study represents one of the first 
steps toward the advancement of siRNA uptake and imaging strategies in the same delivery system, 
essential for cancer therapy [18]. 
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Figure 6. In vivo imaging of siRNA delivery and silencing in tumours. (A) Step-by-step synthesis of the 
MN-NIRF-siGFP probe, by the sequential conjugation of three different entities onto magnetic nanoparticles. 
(B) The resultant probe consisted of magnetic nanoparticles labeled with near-infrared Cy5.5 dye (NIRF) and 
linked through two different linkers to membrane translocation peptides (MPAP) and siRNA molecules 
targeting GFP (siGFP). In vivo imaging of MN-NIRF-siGFP silencing in tumours. (C) In vivo NIRF optical 
imaging of mice bearing bilateral 9L-GFP and 9L-RFP tumours 48 h after intravenous probe injection. (D) 
Correlative ex vivo fluorescence optical imaging showed a significant drop in fluorescence intensity in 9L-GFP 
tumours (P = 0.0036). There was no evidence of silencing in saline injected controls. (E) Confocal microscopy 
of frozen tumour sections indicated the presence of the probe in both 9-GFP and 9L-RFP tumours (blue). Scale 
bar, 20 mm. (F) Quantitative RT-PCR analysis of GFP expression performed on total RNA extracted from 9L-
GFP tumours from mice injected with either MN-NIRF-siGFP, a mismatch control or saline solution. 
Reproduced and adapted with permission [18]. Copyright 2015, Nature Publishing Group. 
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2.3. Mesoporous Silica Nanoparticles for siRNA delivery 
Mesoporous silica nanoparticles (MSNs) are another important inorganic material that have been used 
for siRNA delivery [60]. The large surface area of the pores allows the particles to be filled with large 
amounts of small molecules of siRNA. The first study about siRNA MSNs was reported in 2009 by 
Xia et al., evaluating the role of polyethyleneimine coating in the enhancement of the cellular uptake 
of MSNs for the safe delivery of siRNA and DNA constructs [61]. After that, several MSN based 
systems for cancer therapy have been reported to deliver siRNAs in cells, usually through endocytosis 
[31,62-65]. 
For instance, Li et al. described the synthesis of MSN functionalized with a cationic polymer  (PEI) 
and a fusogenic peptide used to enhance endosomal escape and consequently improving siRNA-
induced silencing gene expression both in vitro and in vivo [65] (Figure 7). 
Another application of MSNs is their use to enhance efficacy of chemotherapy. Hom et al. have 
exploited the large capacity of MSNs to efficiently load a cancer chemotherapeutic, such as 
doxorubicin (Dox) together with Bcl2-siRNAs. The authors observed that both Bcl2-siRNA and Dox 
were released into cells. In order to silence the multi-drug resistant pump of Bcl2 gene, enhancing the 
effect of doxorubicin [64]. 
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Figure 7. A mesoporous silica nanoparticle-PEI-fusogenic peptide system for siRNA delivery in cancer 
therapy. Flowchart illustrating the preparation of siRNA delivery vectors based on magnetic mesoporous silica 
nanoparticles (M-MSNs): (A) Encapsulating siRNA molecules into the mesopores of M-MSNs (M-
MSN_siRNA); (B) Synthesizing PEI-embedded M-MSN_siRNA composite (M-MSN_siRNA@PEI); (C) 
Conjugating KALA peptides onto the surface of M-MSN_siRNA@PEI (M-MSN_siRNA@PEI-KALA). (D) In 
vitro gene silencing process initiated by M-MSN_siRNA@PEI-KALA: (1) the internalization of nanocarriers 
into cells; (2) the endo-lysosomal escape of delivery vehicles; (3) the release of siRNA into cytoplasm from the 
vectors. (E) In vivo cancer treatment through injecting M-MSN_siRNA@PEI-KALA delivery vehicles into 
tumour region. In each step, the blue sphere with white dots represented M-MSNs, the brown double helix 
represented siRNA, the orange random coil represented PEI and the light greenwave line represented KALA 
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peptide. (F) Representative photos of the A549 tumours in mice, which were taken at days 10, 20 and 30. 
Reproduced and adapted with permission [65]. Copyright 2015, Elsevier.  
 
 
2.4. Quantum-Dots (QDs) as vehicles for siRNA 
The first study reporting about siRNA QDs was described in 2007 by Tan et al. The authors reported 
the QD-based nanoparticles for targeted silencing of HER2/neu gene via RNAi [66]. After this study, 
siRNA-QDs as light-emitting nanoparticles [67] have been extensively used for gene silencing 
approaches [21,68-70]. One of the most promising features of siRNA-QDs is the proton-sponge 
effect. In more detail, Yezhelyev et al. developed multifunctional semi-conductor nanoparticles for 
siRNA delivery and imaging based on the use of QDs and proton-absorbing polymeric coatings 
(proton-sponges) (Figure 8). The “proton-sponge effect” occurs when unprotonated species can 
absorb protons as they are pumped into the lysosome, resulting in more protons being pumped in 
leading to an increased influx of Cl
–
 ions and water, resulting in swelling and rupture of the lysosomal 
membrane with subsequent release of its contents into the cytoplasm (Figure 8). The authors 
demonstrated a dramatic improvement in gene silencing efficiency and simultaneous reduction in 
cellular toxicity, when compared with existing transfection agents using the proton sponge effect. 
These nanoparticles were particularly designed to address longstanding barriers in siRNA delivery 
such as cellular penetration, endosomal release, carrier unpacking, and intracellular transport. These 
particular nanoparticles are also dual-modality optical and electron-microscopy probes, allowing real-
time tracking and ultrastructural localization of QDs during the delivery and transfection processes 
[70]. 
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Figure 8. Rational design of proton-sponge coated quantum dots and their use as a multifunctional 
nanoscale carrier for siRNA delivery and intracellular imaging. (A) Chemical modification of polymer-
encapsulated QDs to introduce tertiary amine groups, and adsorption of siRNA on the particle surface by 
electrostatic interactions. (B) Schematic diagram showing the steps of siRNA-QD in membrane binding, 
cellular entry, endosomal escape, capturing by RNA binding proteins, loading to RISC, and target degradation. 
(C) Schematic illustration of the proton-sponge effect showing the involvement of the membrane protein 
ATPase (proton pump), osmotic pressure build-up, and organelle swelling and rupture. For optimized silencing 
efficiency and cellular toxicity, the QD surface layer is composed of 50% (molar) carboxylic acids and 50% 
tertiary amines. The optimal number of siRNA molecules per particle is approximately two. Reproduced with 
permission [70]. Copyright 2015, American Chemical Society. 
 
 
Nevertheless, the major drawback of using QDs as multifunctional imaging probes and delivery 
systems is their inherent cytotoxicity, as most of the well-established QDs are composed of highly 
toxic chemical elements, such as cadmium or selenium [71]. Encapsulation of these QDs into 
polymers may be the key to solving some issues related to acute toxicity but may decrease their 
intrinsic potential as vehicles for delivery. 
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Although nontoxic QDs for imaging and siRNA delivery in vitro have been developed recently 
[68,72], a meticulous analysis of their long-term cytotoxicity is necessary before they can be used in 
vitro and especially in vivo biomedical applications.  
 
 
2.5 Inorganic-organic conjugates as delivery vectors for RNAi 
Although some examples of inorganic-organic systems have been already described in previous 
sections, it is important to highlight the significance of this type of siRNA delivery vehicles. These 
conjugates are formed by an inorganic core that provides the system with special properties such as 
optical and magnetic behaviour, and an organic coating made of different biomolecules such as 
polymers or lipids, used for increasing biocompatibility while serving as anchor points for the siRNA. 
Regarding the use of polymers in the organic shell, the most frequently used polymer is PEI due to its 
positively-charged nature that can bind to siRNA and also induce the disruption of endosomal 
membrane, facilitating the siRNA release into the cytoplasm [73-75]. In fact, PEI (MW 25 kDa) has 
been used very efficiently as delivery vector, although its usage in biological applications is strongly 
limited because of its toxicity. This new approach of combination with inorganic nanoparticles seeks 
reducing the amount of PEI needed and therefore its toxicity while exploiting the advantages it 
presents for siRNA delivery. In an attempt to reducing the toxicity shown by PEI, it has been also 
reported the use of carbohydrate-derived polymers (i.e. dextran or chitosan [66,76]), and amphiphilic 
polymers such as PEG [38,77], known for reducing opsonisation and increasing the circulating time of 
these conjugates. 
In the same direction, several groups have developed inorganic-organic conjugates using lipid 
coatings [39,50] or even dendrimers [78] such as PAMAM [79] that may increase cellular uptake in 
order to enhance the efficacy of these systems searching for the ideal vector. 
More information and examples will be provided in next section regarding the design and 
functionalization of inorganic nanoparticles. 
 
 
3. Functionalization of inorganic nanoparticles with siRNA 
The use of inorganic nanoparticles as carriers for siRNA has expanded amazingly during the last 
decade, revealing these new materials as excellent candidates for gene therapy in order to replace viral 
vectors and their inherent disadvantages [80]. 
The success of the therapy is highly dependent on the effective conjugation between nanoparticles and 
the siRNA, as well as the nature of this attachment. At a first glance, a strong interaction is desirable 
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to maintain stability while the system remains in the bloodstream until reaching the target cells, being 
internalized and escaping from the endosome if necessary. However, once in the cytosol the siRNA 
needs to be capable of being incorporated into the RISC complex to initiate the interference 
mechanism, so it should be completely or partially released from the carrier [81]. 
Attending to the nature of the interaction between siRNA and inorganic nanoparticles, there are three 
main approaches: ionic, covalent and encapsulation. Attachment may be established directly to the 
core of the nanoparticle [38,82] or through intermediates, such as polymers [83,84], dendrimers 
[79,85] and short linkers [18,86], among others. 
 
 
3.1. Ionic approach 
As with other types of nucleic acids, siRNA is negatively charged due to the presence of phosphate 
groups in its backbone. For this reason the most common and maybe the simplest strategy for 
conjugation is establishing ionic interactions with cationic species. 
Although it may seem to be a weak attachment, by modulating the number of positive charges it is 
possible to increase the points of interaction and, therefore, the strength of the ionic bond. 
The most frequent functional group used are amines as they are positive at values of pH under their 
pKa (such as the physiological pH) being able to attach to the siRNA. Besides, it has been described 
their ability to induce endosomal escape by a mechanism usually known as “proton-sponge effect” 
(see Figure 9) [87]. A special type of amines are quaternary ammonium groups whose main feature is 
being positively charged in the whole range of pH ensuring an effective conjugation in all kind of 
media. These groups and different cations can be found either on the surface of the nanoparticles or in 
molecules previously attached ionic or covalently to the carrier.  
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Figure 9. The “proton-sponge effect”: unprotonated amines can absorb protons as they are pumped into the 
lysosome, resulting in more protons being pumped in leading to an increased influx of Cl
–
 ions and water, 
resulting in swelling and rupture of the lysosomal membrane with subsequent release of its contents into the 
cytoplasm. 
 
 
The simplest system consists on the direct conjugation of the siRNA to the core of cationic 
nanoparticles such as quantum dots coated with silica [82], calcium phosphate nanoparticles [88], 
carbon nanotubes [89] and layered double hydroxide nanoparticles [90,91]. 
However, it is more frequent to find hybrid systems composed by the inorganic core and different 
coatings, which provide the positive charges needed.  
The most universal systems reported are based on the functionalization of the nanoparticles with 
cationic polymers, especially with PEI and polylysine (PLL) with many variations. PEI has been 
described using different kinds of nanoparticles directly adsorbed on negatively charged materials 
[74,92] or covalently attached by amination [93]. There are many examples of the functionalization of 
AuNPs [94,95], MNPs [54,96-98], SiNPs [61,99,100], with PEI of different molecular weights 
[61,101] or even modified with labile bonds like acetal [102]. In relation to the PLL, this polymer has 
been used previously modified with a terminal cysteine for the direct attachment to AuNPs [103], 
conjugated to epoxysilanes [62] and as part of a layer-by-layer system with siRNA [104]. However, 
more polymers have been used for conjugation, e.g. poly-arginine [105], derivatives of polymaleic 
acid [70] and ethylmethacrylate [106].  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
REVIEW           NANO TODAY 
24 
 
Besides, Pierre et al. used a combined functionalization of MNPs with two kinds of polymers, being 
able to modulate the net charge more effectively [107]. Lately, a new kind of polymer named “charge-
reversal” has appeared, whose main property is the ability to change their charge as a function of pH, 
being positive at neutral pH and negative in acidic conditions. One of the best examples is PAH-Cit, 
which is also effective in reducing the possible cytotoxicity induced by highly positive species 
[29,108,109]. 
Other possibility includes cationic dendrimers [110,111] like in the case of the dendriworms made 
from magnetic nanoparticles by Bhatia et al. and coated with Poly(amido amine) dendrimer 
(PAMAM) [79] (Figure 10) or lipidic species such as cholesterol [23], 
dioleoylphosphatidylethanolamine (DOPE) [45] or the commercially available transfection agent 
Metafectene® [98], or polyurea dendrimers (PURE-G4) [112]. 
Last but not least, many other molecules have been described that use other chains like aminoacids 
(lysine and arginine [68,113]), alkyl chains with either one or two amine groups (Cetyltrimethyl 
ammonium bromide (CTAB 60) [114], cysteamine [46,115], Hexamethylendiamine (HMDA) [116], 
2-aminoethyltrimethylammonium chloride [28]) and protamine [117]. 
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Figure 10. Functional delivery of siRNA in mice using dendriworms. Synthesis and characterization of 
dendriworms: (A) synthesis scheme; (B) siRNA binding characteristics. Dendriworm and siRNAs were 
allowed to bind in varying ratios and run on a gel. Strong binding between the dendriworm and siRNA at 
roughly 1:10 ratio (measured using iron core concentration) prevents siRNAs from entering the gel. In vivo 
knockdown of EGFR expression in transgenic mice: (C) EGFR siRNA delivered with dendriworms, (D) GFP 
siRNA delivered with dendriworms, (E) EGFR siRNA delivered with nanoworm-NH2, and (F) quantitative 
analysis of EGFR expression per cell or NP uptake relative to number of cells (DAPI). Scale bar, 100 m. 
Reproduced with permission [79]. Copyright 2015, American Chemical Society. 
 
 
 
3.2. Covalent approach 
For the covalent approach there are many different options determined by the nature of the 
nanoparticles and the compounds used as stabilizers of the system. However, all these strategies have 
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in common the use of thiolated siRNA, generally synthesized as disulphide and reduced with 
dithiothreitol (DTT) [21,118] or tris(2-carboxyethyl)phosphine (TCEP) [73] prior to the attachment. 
An important issue that should be taken into account is the nature of the bond in terms of labile or 
non-labile and the influence of the attachment of the antisense or the sense strands of the siRNA (see 
Figure 11) [119]. 
 
 
Figure 11. Probing the effect of conjugation strategy on gene silencing by QD-siRNA conjugates. (A) 
Scheme for probe synthesis. (B) Characterization of the probes. (Left) Gel electrophoresis of QD-siRNA 
conjugates. Conjugation with labile cross-linkers (SPDP and SMPT) releases the conjugated siRNA upon 
treatment with glutathione. Arrow indicates unbound siRNA. (Middle) Gel electrophoresis of QD-siRNA with 
nonlabile maleimide cross-linker indicating the absence of unbound siRNA. (Right) Intracellular delivery of 
QD-siRNA conjugates by electroporation in modified HeLa (GFP-Ago2/Luc-CXCR4) cells. QD-siRNA 
conjugates are in red, green is Ago2-GFP, and the nuclei are stained with DAPI (blue). Scale bar, 30 μm. 
Reproduced with permission [119]. Copyright 2015, American Chemical Society. 
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The most direct strategy is the chemisorption of thiolated siRNA on AuNPs, due to the strong bond 
formed between gold and sulphur atoms [120]. Taking advantage of this simple interaction and based 
on previous functionalization of AuNPs with DNA [121-125], there are plenty of examples describing 
the analogue conjugation of siRNA with systems of different sizes [126-128] and shapes [39,129].  
In fact, we reported the design of two approaches (Figure 12) for the binding of siRNA molecules to 
multifunctional AuNPs. The binding of the negatively charged siRNA through ionic interactions to 
the modified gold surface (ionic approach) and the use of thiolated siRNA for the binding to the 
nanoparticle through the strong interaction gold-thiol (covalent approach) [28]. The two approaches 
had huge differences in terms of silencing efficacy in vitro, proving that the method for siRNA 
binding together with the targeting motifs plays a crucial role in the efficiency of gene silencing via 
RNAi-NPs (Figure 11).  
 
 
Figure 12. Gold nanoparticles functionalized with multiple biomolecules: PEG, cell penetration peptide (TAT), 
ammonium quaternary groups, and siRNA. Two different approaches were employed to conjugate the siRNA 
to the AuNPs: (A) ionic approach, interaction of the negatively charged siRNA to the modified surface of the 
AuNPs through ionic interactions; (B) covalent approach, use of thiolated siRNA for gold thiol binding to the 
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NPs. The graphs show the quantitative assessment of RNAi efficiency. HeLa cells were transfected with the 
recombinant vector psiCHECK-2, encoding for the fusion protein Renilla luciferase-myc. Decrease of Renilla 
luciferase activity induced by c-myc-siRNA was expressed as percentage of normal luciferase activity. 
Unrelated siRNA (cont-siRNA) bound on the AuNPs; naked or lipofectamine delivered siRNA were included 
as negative and positive RNAi controls, respectively. Data marked with asterisks are statistically significant 
relative to the corresponding NP-ion/cov with control siRNA as calculated by paired Sample t test (**, P  
0.0001; *, P  0.001). Reproduced and adapted with permission [16,28]. Copyright 2015, American Chemical 
Society and Frontiers. 
 
 
 
In addition, the influence of different parameters such as the thiolation degree of the siRNA [130], the 
strand involved in the attachment [127], the need of increasing the amount of salt to improve the yield 
of the functionalization [24] and the possible release of the siRNA with DTT or the glutathione 
present in the cytosol [38], are also to be taken into account. 
The remaining strategies for covalent attachment involve compounds with two reactive groups that 
serve as linkers. The most frequent linker is the Succinimidyl 3-(2-Pyridyldithio)Propionate (SPDP) 
and all of its derivatives (LC-SPDP and sulfo-LC-SPDP). This compound effectively reacts with 
amine groups on one end (N-hydroxisuccinimide group forming an amide bond) and thiols on the 
other (pyridil disulfide group that forms a new disulfide bond). Its use has been described with almost 
all types of inorganic nanoparticles such as AuNPs [25], MNPs [131], QDs [21,119] and carbon 
nanotubes [17,132]. It has also been reported in the use of products with the same reactive groups as 
SPDP (i.e. 4-succinimidyloxycarbonyl-α-methyl-α-[2-pyridyldithio]toluene (SMPT) [119]) or similar 
(i.e. 3-(2-pyridyl)-dithiopropionic acid pentafluorophenyl ester (PTPPf) [133]), in which different 
modifications have been introduced. These linkers are very interesting because the disulfide bond they 
establish with the siRNA is actually a labile bond that can be reduced in the cytosol with the levels of 
glutathione found inside cells (~10 mM), much higher than levels on the bloodstream, allowing the 
release at the desired place. 
Another option consists of forming non-labile bonds with siRNA by using linkers like m-
Maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) [18], N-gamma-Maleimidobutyryl-
oxysuccinimide ester (GMBS) [33], Succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate 
(SMCC) [21] and their sulfonated derivatives, which have a terminal maleimide group that react with 
thiols to form a thioether bond [133]. It has also been studied the influence of nature and length of the 
chains between the succinimydil group and the maleimide [119]. Following with the formation of 
non-labile bonds, the linker SIA (Succinimidyl iodoacetate) that has a N-hydroxisuccinimidyl ester 
and a iodoacetyl group, is interesting once it introduces less atoms in the final structure than others 
[56,73]. 
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3.3. Encapsulation 
Encapsulation is the least common approach, as it can be used with only a few types of inorganic 
nanoparticles, such as calcium phosphate nanoparticles [44,114,134], which can encapsulate the 
siRNA when added in the synthesis step. Afterwards, these nanoparticles induce the endosomal 
escape by disruption of the endosome membrane and upon degradation release the siRNA directly in 
the cytosol (Figure 13) [134]. 
 
 
Figure 13. Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. 
(A) The formation process of liposome/calcium/phosphate (LCP) nanoparticles. (B) The hypothesized release 
process of siRNA entrapped in LCP after endocytosis to the endosome. There are four steps for siRNA released 
from LCP: 1) The LCP enters the cell through endocytosis and stays in the endosome; 2) The CaP core is 
dissolved at low pH, causing NP de-assembly; 3) The dissolved calcium and phosphate ions increase the 
osmotic pressure and cause endosome swelling and 4) The endosome bursts and releases the siRNA, calcium 
and phosphate ions into the cytoplasm. (C) In vivo luciferase gene silencing effects of different formulations at 
the dose of 1.2 mg/kg. The luciferase activity in H-460 cells was measured after 24h of the I.V. injection with 
different siRNA formulations. Reproduced and adapted with permission [134]. Copyright 2015, Elsevier. 
 
 
Other types of nanoparticles capable to encapsulate siRNA are mesoporous silica nanoparticles with 
large pores [31,135,136] embedding the siRNA inside them under strong dehydrating conditions 
[63,137]. Carrying the siRNA encapsulated shows some advantages over ionic adsorption [65], 
including avoiding the use of large amounts of positively charged substances that can increase toxicity 
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and the fact that more groups are available on the surface for the effective attachment of targeting 
molecules, thus improving the system’s specificity. 
Lastly, although not very frequent, there are also a few reports on the encapsulation of siRNA inside 
carbon nanotubes [138,139]. 
 
 
4. Evaluation of silencing strategies in vitro 
The methods for evaluating the success and degree of silencing diverge greatly. A variety of 
techniques that determine multiple degrees of cellular complexity, such as the transcript level, the 
protein level and the physiological level, are important to fully understand how effective a strategy 
employed is at producing a silencing effect. Vogel et al. have shown that the abundance of detected 
transcripts can only partially predict protein levels, often by as little as 40%. A further consideration 
for evaluation is that not all transcripts and proteins are created equally; many exhibit a wide range of 
stability and turnover properties (Figure 14) [140].  
  
 
Figure 14. mRNA transcript abundance only partially correlates with protein abundance, typically explaining 
approximately one- to two-thirds of the variance in steady-state protein levels, depending on the organism. This 
trend is evident in data from NIH3T3 mouse fibroblast cells (A) and from a human DAOY medulloblastoma 
cell line (B), where ~30-40% of the variance in protein abundance is explained by mRNA abundance. A 
similarly large fraction of variance can be explained by other factors, which is indicative of post-transcriptional 
and translational regulation and protein degradation. Reproduced with permission [140]. Copyright 2015, 
Nature Publishing Group.  
 
 
In mammalian cells, approximately two molecules of transcript are produced per hour [141], in 
contrast to transcript translation, which can produce tens of copies of proteins per hour. This 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
REVIEW           NANO TODAY 
31 
 
exemplifies the need, when studying silencing strategies, to determine effects not only at the transcript 
level, but also at the protein level. 
 
 
4.1. The Transcript level 
Typically, various modifications of Polymerase Chain Reaction (PCR) are employed when assessing 
the transcript level. The data supplied provide information on the increase or decrease of the target 
gene. A recent paper by Acharya et al. used AuNPs functionalised with a KDEL peptide and loaded 
with siRNA against the gene NOX4 in C2C12 cells [142]. The authors showed that the AuNPs were 
actively uptaken and subsequently reduced the levels of the NOX4 transcript levels by as much as 55% 
in myoblasts after 24 hours. However, they did not investigate whether this level of knockdown was 
paralleled at the protein level, which is necessary to ensure that the siRNA is acting at different levels 
of the cells molecular machinery. In 2012, Han et al. used chitosan conjugated AuNPs and siRNA to 
knockdown the multidrug resistance 1 (MDR1) gene encoding the drug exporter P-glycoprotein (P-gp) 
in HeLa and MCF-7 cells [109]. To assess the knockdown they used semiquantative RT-PCR, and 
found up to 80% knockdown. Although significant at the transcript level, the authors did not directly 
verify whether this high level of knockdown affects the MDR-1 protein expression. Instead, the 
authors indirectly used doxorubicin as a measure of protein knockdown, as the P-gp acts as a drug 
efflux pump. They found fluorescently labelled doxorubicin at more than double the amount within 
cells treated with the siRNA-AuNPs, in contrast to control; showing a correlation between the 
knockdown of the MDR-1 mRNA and the amount to which doxorubicin is uptaken (Figure 15). 
However, there does appear to be a weakening of the effect when moving from the transcript, to 
protein, to physiological level. 
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Figure 15. Enhanced siRNA delivery and silencing gold chitosan nanosystem with surface charge-
reversal polymer assembly. (A) Assembly steps for siRNA/PEI/PAH-Cit/AuNP-CS complexes and pH-
responsive release of siRNA. (B) TEM images of AuNP-CS, PAH-Cit/AuNPCS, and PEI/PAH-Cit/AuNP-CS. 
Insets: Higher magnification micrographs of the assembled nanoparticles. (C) MDR1 knockdown efficacy 
detected by semiquantitative RT-PCR. (D) CLSM images of MCF-7R cells incubated with naked MDR1 
targeted siRNA, PEI/PAH-Cit/AuNP-CS, PEI, and PEI/PSS/AuNP-CS complexed with MDR1 targeted siRNA. 
MCF-7R cells were exposed to free siRNA or vector-complexed siRNA for 48 h, incubated with doxorubicin 
(red) for 24 h, and then subjected to CLSM imaging. Scale bar, 20 μm. (E) Quantitative analysis of intracellular 
doxorubicin uptake. Reproduced and adapted with permission [109]. Copyright 2015, American Chemical 
Society. 
 
 
4.2. The Protein level 
Many examples of silencing have used luciferase activity as an indicator of success [25,29,38,45,46]. 
Although very useful for assessing the concept of AuNPs for silencing, it is of limited scope for 
knockdown studies seeking to target native proteins. The same is true for studies that use GFP as a 
reporter gene. As GFP is not a native protein, it has limited used for further studies, which would 
ideally aim at altering native protein levels by using silencing machinery, such as siRNA, miRNA or 
small molecules [24,25,38]. When verifying protein knockdown, alternative techniques would need to 
be used such as western blots [143], flow cytometry [45] and In-Cell westerns [144]. A recent study 
by Zhao et al. reported the development of AuNPs loaded with siRNA against the epidermal growth 
factor receptor (EGFR) gene, and observed a knockdown efficiency of between 16-38% in MCF-7 
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cells via flow cytometry (Figure 16) [145]. The use of the flow cytometer allowed for the distinction 
between populations of cells, with a better assessment of the siRNA knockdown; in contrast to 
western blots, which use a pooled protein sample from a cellular population.  
 
 
Figure 16. Surface engineering of gold nanoparticles for in vitro siRNA delivery. (A) Schematic illustration 
showing the preparation process of the AuNP-based siRNA vectors together with chemical structures of 
positively charged polyelectrolytes, i.e., PAH, PEI, and PDDA. Confocal fluorescence microscopy images of 
MCF-7 cells treated with AuNP–PAH-1 (B), AuNP–PAH-2 (C), AuNP–PAH-3 (D), AuNP–PAH-4 (E), FAM-
labelled siRNA–Lipofectamine 2000 (F), and FAM-labelled siRNA–PAH (G), respectively. The cell nuclei 
were stained with Hoechst 33258 (blue), and the cell membrane was stained with Rhodamine phalloidin (red). 
The FAM-labelled siRNA appear in green. (H) Apoptosis rates of MCF-7 cells treated with no siRNA (a), and 
NC siRNA loaded by Lipofectamine 2000 (b), AuNP–PAH-3 (c), and PAH (d), respectively, together with 
those recorded from the cells treated with EGFR siRNA delivered by Lipofectamine (e), AuNP–PAH-3 (f), and 
PAH (g), respectively. Reproduced and adapted with permission [145]. Copyright 2015, Royal Society of 
Chemistry. 
 
 
Western blots are still routinely used to evaluate the efficacy of silencing using siRNA. For example, 
siRNA conjugated AuNPs was used against the hepatoma-derived growth factor (HDGF) [146], 
showing considerable reduction of HDGF protein levels in contrast to a scrambled siRNA sequence. 
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However, the authors used an additional [3H]-thymidine incorporation assay (a method to measure 
cell proliferation), treatment with the AuNPs loaded with the functional siRNA significantly arrested 
the cell cycle. The adoption of several techniques, such as western blots and cell functional assays, 
allows for parallel assessment of protein amount and protein function, thus elucidating both the 
efficiency and effect of the silencing on the cell. 
With increasing levels of complexity the initial efficacy of silencing may be weakened by a numerous 
intracellular mechanisms, such transcript turnover, post-translational modification, protein half-life 
and many other intercellular interactions. To fully understand how the silencing target is affected, it is 
vital to assess the functionality at multiple levels, such the transcript, protein or whole cell level before 
testing in vivo.  
 
5. In vivo delivery of siRNA: promises and challenges 
RNAi, and more specifically siRNA, have emerged as powerful tools for sequence-specific post-
transcriptional gene silencing. Nevertheless, the in vivo delivery of siRNAs to the specific target cell 
represents the most challenging bottleneck of RNAi translation into clinical therapeutics. While RNAi 
works well in the laboratory, it has proven to be somewhat problematic in vivo [147]. In fact, recent 
pre-clinical trials have tempered the excitement and triggered extensive efforts to overcome some of 
the major obstacles/limitations of siRNA technology, namely cytoplasmic and systemic delivery of 
siRNAs, renal clearance, target site accumulation after administration, heterogeneous vascular 
perfusion and diffusion, endosomal escape and siRNA recognition by RISC [148,149].  
The success of RNAi therapy is highly dependent on the effective conjugation of siRNA to the 
nanoparticles, but also on several factors that affect RNAi efficiency, such as route of administration, 
circulation time and stability, tissue extravasation, targeting and cell internalization and endosomal 
escape, as delineated below. 
 
Route of administration: Systemic delivery of therapeutic agents is the most convenient application 
route that can potentially reach any target site non-invasively. However, systemic administration of 
siRNA represents a huge challenge since unmodified siRNAs tend to accumulate in the kidneys (40-
fold more than in other organs), whereas siRNA containing nanoparticles often become entrapped in 
the liver [150]. Thus, siRNA therapeutics designed for these tissues can be delivered by local 
administration of siRNA, which encounters fewer cellular barriers. Nevertheless, numerous disease 
target sites, such as liver and spleen, require systemic administration of siRNAs into the circulatory 
system and circulation throughout the vasculature prior to specific tissue accumulation [151]. For 
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specific applications that require targeted systemic delivery, nanocarriers may be functionalized with 
cell-specific ligands that allow receptor-mediated uptake into target cells, such as tumour cells.  
Also, depending on the target tissue, alternatives to injection into circulation may be considered. The 
local application of nanoparticles at or near the target sites might be the method of choice for the 
multitude of pathologies.  
Recently, the in vivo targeting of lung tumours using siRNA/RGD-AuNPs in a lung cancer syngeneic 
orthotopic murine model resulted in successful targeting in the lung following direct intratracheal 
delivery (Figure 17) [27]. Intratracheal instillation is a non-invasive and highly efficacious route of 
administration with high clinical value, and was used to improve NPs distribution in the lungs, and 
avoid liver/spleen non-specific accumulation associated with the systemic administration. In this 
model, significant c-Myc oncogene down-regulation followed by tumour growth inhibition and 
prolonged survival of lung tumour-bearing mice was attained, possibly via αvβ3 integrin interaction. 
The authors suggest that RGD AuNPs-mediated delivery of siRNA by intratracheal instillation in 
mice leads to successful suppression of tumour cell proliferation and respective tumour size reduction, 
without any signal of inflammation [27]. 
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Figure 17. Inflammatory response and therapeutic siRNA silencing through RGD-nanoparticles in a 
lung cancer syngeneic orthotopic mouse model. (A) Engineered nanoparticles modified with RGD and 
siRNA can represent a delivery system of siRNA and a useful tool for sequence-specific gene silencing in a 
lung cancer mouse model. (B) AuNPs@PEG@RGD@siRNA are administered by intratracheal instillation and 
directly delivered to bronchial airways, where the can efficiently target tumour cells, by anchor through RGD 
receptors, such as v3 integrins, expressed in lung tumour cells. Bioluminescent imaging of B6 albino mice 
injected with luciferase-CMT/167 adenocarcinoma cells was performed to serially assed tumour size in each 
mouse, with luciferase activity as a measure for the tumour burden. Images show lung cancer mice and 
respective control lungs with no treatment (C), or with AuNPs@PEG@RGD (D) and 
AuNPs@PEG@RGD@siRNA (E) treatment. These bioluminescence images clearly depict a tumour regression 
(80-90% decrease) in AuNPs@PEG@RGD@siRNA treated group. Reproduced and adapted with permission 
[27]. Copyright 2015, Elsevier. 
 
 
In fact, local delivery can prevent most of the systemic toxicity while simultaneously enabling 
effective concentration and retention of the therapeutic agent. Continuous release of siRNA into the 
local cell/tissue microenvironment can be accomplished by formulating siRNA into biocompatible, 
biodegradable and immunologically inert matrices, like hydrogels [152-154]. These hydrogels can be 
further engineered to interact with specific tissues and to control the nanoparticles´ release kinetics 
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and stability. Intelligent hydrogel-based matrix designs would enable the programming of the 
nanoparticles´ release kinetics to occur in response to extrinsic factors such as light, temperature or 
pH. This can be combined with the ability to track the release using optical imaging, making these 
hydrogels ideal candidates for the local delivery of siRNAs [154-156]. 
Implantable or locally injectable NP-embedded hydrogels can be exploited to deliver siRNAs to target 
tissues. Nanoparticles can also be delivered subcutaneously by intradermal injection [157], epidermal 
electroporation [158] or via microneedles [159] but also as topical applications using hydrogel 
scaffolds or patches [154]. 
 
Circulation time and stability: Nanoparticles can be modified to protect and shield the siRNAs from 
endogenous clearance mechanisms. Compared to conventional transfection agents, nanoparticle-
conjugated siRNAs have been shown to be less susceptible to degradation by nuclease activity, to 
exhibit greater cellular uptake and to have a higher siRNA effective concentration, all of which have 
accelerated siRNA research into this delivery method over the past few years. Unfortunately, linking 
the siRNA to a nanoparticle alone does not protect it from clearance. Blood serum components 
interact with siRNA-nanoparticles and mark them for uptake via the mononuclear phagocyte system 
(MPS), especially by Kupffer cells in the liver [14,150]. The use of nanoparticles composed of 
hydrophilic polymers including acrylic acid, acrylamide, and maleic anhydride polymers and 
copolymers, as well as allylamine, ethyleneimine, oxazoline (for example, Polyethylene glycol, 
Polyethylenimine, Poly(acrylic acid), Poly(vinyl alcohol), Poly(N-isopropylacrylamide)) inhibits 
serum protein binding and clearance by immune cells which thereby drastically increases their 
circulation time [14,160]. This method is used to increase circulation time by reducing the non-
specific interaction of nanoparticles with serum proteins or unspecific immune cells or targeted 
tissue/organs [14,160]. In fact, the great majority of siRNA–NP conjugates require functionalization 
with PEG molecules to achieve equivalent stability to DNA–NPs, which may have something to do 
with the capacity loading of the different molecules due to singular hydrophobicity and/or 
hydrophilicity, molecular weight and charge density properties between RNA and DNA [161]. 
 
Renal clearance: Renal clearance is another challenge as naked siRNA, with average diameter of less 
than 10 nm, is rapidly excreted from the blood compartment through renal clearance [148]. To avoid 
renal clearance, nanocarriers chemically modified to increase the retention time of the siRNAs in the 
circulatory system (e.g. cationic polymers) are frequently proposed [162,163]. The interaction of 
siRNA with serum components may affect their delivery, some serum proteins in the bloodstream can 
tag the delivery vehicles for uptake via the MPS. Actually, the stimulatory or anti-stimulatory action is 
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typically due to binding of proteins in the blood, which influence the nanoparticles uptake by cells and 
the interaction with other blood components [14]. This can be overcome by shielding the surface of 
the delivery vehicle with hydrophilic polymers including acrylic acid, and maleic anhydride polymers 
and copolymers, as wells as allylamine, ethyleneimine, oxazoline (for example, Polyethylene glycol, 
Polyethylenimine, Poly(acrylic acid), Poly(vinyl alcohol), Poly(N-isopropylacrylamide)).  
 
Tissue/Tumour extravasation: In vivo delivery of siRNAs also shows some limitations concerning 
vascular extravasation and diffusion in target tissues, since it is required that the siRNA or nanocarrier 
extravasate from the blood stream into the extracellular matrix, and then diffuse to reach all 
cells[164]. For instance, several solid tumours have defective vasculature and poor lymphatic 
drainage, due to their rapid growth, resulting in an enhanced permeability and retention (EPR) effect, 
facilitating the delivery of therapeutics to this region [165,166]. This effect allows nanocarriers to 
accumulate specifically at the tumour site [167]. Tumour cells are supplied by blood capillaries that 
perfuse the cells of the tissue, and nanocarriers can passively accumulate or anchor through targeting 
moieties to biomarkers overexpress by tumour cells.  
Nanoparticles’ size is critical for efficient tissue or tumour delivery. Nanoparticles in the size range of 
10-100 nm are generally accepted as efficient delivery agents, determined by in vivo clearance, 
biodistribution and toxicity. Particles of less than 10 nm are subject to renal clearance, while larger 
particles >15µm are removed from the circulation by the reticulo-endothelial system (RES) in the 
liver and spleen [58,59]. The RES (also known as macrophage or mononuclear phagocyte systems), is 
a network of cells located throughout the body that support the elimination of small particles, also 
involved in the identification of foreign substances in blood and tissues [168]. Because of the effective 
elimination of NPs by the RES, the optimal delivery of NPs to target sites through intravascular 
delivery constitutes a challenge. Therefore, the size of nanoparticles and their payload should be large 
enough to prevent rapid leakage in blood capillaries but at the same time small enough to escape from 
the scavenge of macrophages in the RES, such as the liver and spleen or being cleared out by the 
kidneys. Appropriately sized nanoparticles can be chemically modified to increase their retention time 
in the circulatory system, using cationic polymers as described [162,163] or directly engineered to 
target phagocytic cells to increase uptake and antigen presentation [169]. 
Usually, nanocarriers with ≤ 400 nm in diameter can easily extravasate and accumulate in the leaky 
vasculature of solid tumours [148,170]. Taking advantage of the EPR effect several nanocarriers 
(~100 nm diameter) for in vivo siRNA delivery have been produced, especially by steric stabilization 
of nanoparticles via PEGylation and also with active targeting ligands, such as antibodies, peptides, 
aptamers [24,30,171-174]. 
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Targeting and cellular uptake: Once the siRNA is inside the target tissue it has to reach the target 
cells while excluding healthy cells. Nanoparticles can be functionalized with cell-specific ligands that 
allow receptor-mediated uptake into target cells, for example markers which are overexpressed on 
tumour or immune cells. Additionally, the surface charge on the nanoparticle is a crucial factor that 
affects cellular internalization and also determines potential in vivo circulation. Positively charged 
particles have been shown to exhibit increased internalization compared to neutral or negatively 
charged nanoparticles. In general, positively charged particles are more efficiently taken up because of 
electrostatic interactions between the positively charged particle surface and the negatively charged 
cellular membrane. Conversely, nanoparticles with negative surface charges typically exhibit low 
cellular internalization; however these nanoparticles can circulate longer in vivo and thus, better 
accumulate at tumour sites [175,176]. 
 
Endosomal escape: In order to activate the RNAi pathway, siRNAs must be successfully delivered 
into the cytoplasm, a process challenged by the large size and hydrophilicity of the nanoparticles, 
limiting their ability to cross the cell membrane in the absence of a transfection agent. Moreover, the 
cellular uptake of nanoparticles (endocytosis) as well as their subsequent discharge (exocytosis) is 
affected by their shape, size and charge. Generally, small (<200 nm) positively charged nanoparticles 
adsorb to the negatively charged plasma membrane, followed by clathrin-dependent endocytosis. In 
contrast, larger particles (>200 nm) enter the cell by receptor- and clathrin-independent endocytosis 
[177]. The uptake pathway can greatly influence the interaction/effect of particles on cellular 
responses. 
Therefore, from a cell’s point of view, a critical step which also requires novel materials, is the 
endosomal release of siRNA after transfection across the cell membrane. Most of the described 
systems get trapped in the lysosomes compromising functionality and effectiveness of their siRNA 
cargo. Once the nanoparticle is taken up by the target cells via endocytosis, its release from the 
endosome into the cytoplasm is the next challenge. Many of the described systems/vehicles get 
trapped in the endosome, which fuses with lysosomes (i.e. endolysosome) thereby destroying the 
siRNAs. Therefore, the endosomal escape or siRNA accessibility to form the RNA-induced silencing 
complex (RISC) requires substantially more circulation time, as well as specific targeting via 
fusogenic peptides that promote endosomal escape [178] or lysosomotropic compounds/surfactants 
[179] that promote lysosomal release (see Figure 18).  
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Figure 18. Fusogenic peptides (A) versus lysosomotropic compounds/surfactants (B) for endosomal 
escape and lysosomal release, respectively. These two types of compounds can greatly enhance the 
gene silencing of siRNA-containing nanoparticles.  
 
 
 
6. The fate of inorganic nanovectors for gene silencing 
Even the most successful siRNA vector might be useless if it induces undesirable toxicity on either a 
cellular or systemic level. In the case of nanomaterials engineered for gene silencing, it appears 
obvious that the introduction, the persistence and the transformation of inorganic nanoparticles into 
the cytoplasmic environment may represent a risk for cell homeostasis and viability. For such reasons, 
it would be warmly desirable that the nanomaterials employed might be metabolised to innocuous by-
products or harmlessly excreted from the cells in a reasonable period of time after having completed 
their function. Over the last decade maximising the silencing efficiency of siRNA-conjugated 
nanoparticles has been the major concern of researchers operating in this field, while limited attention 
has been dedicated to understand the fate of these nanovectors after siRNA delivery in vitro and in 
vivo. As consequence, our knowledge about the metabolism (transformation, degradation) of siRNA-
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conjugated NPs is still in its infancy and hence requests intensive investigation before reaching 
clinical trials.  
As rule of thumb, after biomolecule delivery the fate of inorganic nanovectors is strictly related to the 
physico-chemical properties of nanostructures such as size, charge, chemical composition and coating. 
Besides the intrinsic properties of nanomaterials, internalization routes and intracellular localization 
also play a key role in determining nanovector fate and clearance. For instance, NPs often ultimate 
their intracellular journey in the lysosomes, and within these organelles their fate depend on the 
resistance to the unfavourable environment created by combined effects of acidic pH, digestive 
enzymes and chelating agents. 
It is generally accepted that gold NPs present high stability against oxidation, which makes them less 
prone to degradation in biological compartments [180]. Consequently, these nanoparticles are often 
secreted apparently intact from cells, preserving their chemico-physical properties. Bartczak et al. 
investigated the endothelial cell clearance of two types of peptide-coated gold nanoparticles of similar 
size and charge but different functional coatings [181]. The authors demonstrated that peptide capping 
influenced NP exocytosis profiles. These variations in exocytosis profiles strongly correlated with 
different nanoparticle uptake mechanisms and the fate of particles in the cells. In addition, the authors 
demonstrated that excreted Au NPs conserved their colloidal stability after exocytosis. Recently, 
Marchesano et al performed the first study of siRNA functionalized gold nanoparticles trafficking at 
whole animal level, using the aquatic invertebrate H. vulgaris [182]. In more details, the authors 
demonstrated that AuNPs could be internalised through a multitude of routes (membrane 
translocation, endocytosis and vesicle loading) independently from the siRNA cargo, while the 
efficiency of uptake was strictly dependent on the surface charge. A dynamic study performed entirely 
at ultrastructural level showed AuNP accumulation into lysosomes 24 h post incubation, and more 
interestingly revealed different exocytosis mechanisms, including membrane shedding, lysosomal 
release and for the first time nanovesicle mediated secretion, likely through exosomes. In contrast to 
gold nanoparticles, the degradation of other inorganic nanovectors is well documented. A striking 
multiscale approach, proposed by Levy et al., was employed to profile the intracellular processing and 
degradation of MNPs in mouse over three months. The authors reported that after injection MNPs 
presented a change of the magnetic behaviour and the loss of their superparamagnetic properties. At 
subcellular scale, they proved that large clusters of MNPs accumulated prevalently into lysosomes of 
tissue-resident macrophages (spleen, liver, adipose tissue) and gradually degraded over time, whereas 
iron was recycled into ferritin storage proteins [183]. Regarding colloidal mesoporous silica 
nanoparticles (MSNs), a first study on the biodegradation has been carried out in situ by using a 
simulated biological fluid (SBF). Long-term incubation in SBF produced a progressive degradation of 
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silica nanostructrures. Interestingly, the authors reported that a PEG-shell can effectively slow down 
the degradation of the mesopore system suggesting that these NPs are highly promising candidate for 
targeted and controlled drug release [184]. Subsequently, Zhai et al, demonstrated that the degradation 
of MSNs took place initially both in the cytoplasm and the lysosomes, and subsequently only in the 
lysosomes of human umbilical vein endothelial cells (HUVEC). Noteworthy, the silicon content in 
culture medium increased as function of NP degradation indicating that HUVEC excreted the 
degradation product from the intracellular environment [185]. 
While it is generally assumed that the fate of gold, iron oxide and silica nanoparticles does not pose a 
real threat, heavy metal (e.g. Cadmium, Cd; Indium, In) release from semiconductor nanocrystals may 
severely limit the use of QDs for biomolecule delivery. It is well documented, in fact, that capped and 
uncapped nanocrystals undergo degradation producing harmful effects in vitro and in vivo [186-189]. 
For instance, surface oxidation through a variety of pathways led to the formation of reduced Cd on 
the QD surface and release of free cytotoxic ions. Most of these reactions occur in endosomes, 
lysosomes and peroxisomes [184]. Therefore, despite the above-mentioned successful approaches of 
gene silencing based on QDs, long-term toxicity of these conjugates may be a problem and needs to 
be carefully evaluated in order to achieve a critical assessment of risk versus benefit of the use of QDs 
for RNAi. 
 
7. Conclusions and future perspectives: where we are for the next 15 years? 
Some of the nanomaterials and strategies described here will most likely revolutionize our 
understanding in how siRNA nanoparticles can interact and influence or be influenced by biological 
mechanisms. This will in turn push forward the clinical practice through their integration in future 
therapy platforms. However, further research into the fundamental mechanisms of in vivo gene 
therapy using these nanoconjugates could unveil new dimensions of nanoparticle-mediated gene 
silencing that will have thoughtful consequences for understanding gene regulation, and could also 
affect the development of functional genomic and therapeutic applications. In vivo 
transfection/administration will also require optimization for both passive and active targeting 
mechanisms.  
Moreover, another important issue that remains unclear is how safe siRNA nanoparticles will be 
tracked following incubation/injection/implantation, and in particular how clearance and recycling of 
these materials occurs in long-lasting and sustained release platforms. Future in vivo work will need to 
cautiously consider the accurate option of chemical modifications to incorporate into the nanoparticles 
to avoid off-target effects. Some limitations for the correct design and application of nanoparticles, 
such as pharmacokinetics and pharmacodynamics, biodistribution, and side effects of the nanotherapy; 
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safety profile of nanomaterials before and after conjugation and toxicity, needs to be clarified to 
validate efficient clinical appliance. This is especially important for the establishment of a regulatory 
approval of these siRNA nanoconjugates. It is, therefore, imperative to learn how advances in 
nanosystem’s capabilities are being used to identify new diagnostic and therapy tools driving the 
development of personalized medicine in different disease states and pathologies and recognize how 
to translate nanotherapy data into an actionable clinical strategy and discuss it with industry leaders. 
Last but definitely not least, personalized materials for the delivery of siRNA nanoparticles are 
needed. The archetype for diseases’ treatment has to change from relatively nonspecific nanodelivery 
agents to tuned, selective, cellular/molecular and mechanism-based devices. No studies reported so far 
use tuned materials to respond either to cellular microenvironment in specific pathologies, different 
stages of disease or tune materials to different dosages in order not to overload cells with siRNAs. In 
fact, most of the current approaches lack control over some critical features such as stimuli 
responsiveness and biodegradation for siRNA release in light of the microenvironment conditions nor 
the disease type and stages. We believe this will definitely represent the next 15 years on siRNA 
delivery using nanotechnology. 
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Table 1. Examples of nanoparticle-based siRNA delivery systems. 
 
 
 
Nanoparticle type 
Conjugation 
type 
Target gene Biological system 
Efficiency of silencing/ 
detection method 
Ref 
Magnetic  NP 
Covalent binding 
GFP/RFP/ 
survivin 
9LGliosarcoma 
cells 
mouse 
50% -fluorescence intensity 
>80% -qRT-PCR 
[18] 
Absorption via 
lipids 
luciferase HeLa cells 90% - enzymatic activity [28] 
Magnetic 
nanobeads 
Surface 
absorption 
GFP HeLa cells n.d. -fluorescence intensity [22] 
Gold NP 
Gold-thiol 
conjugation 
luciferase HeLa cells > 70% -enzymatic activity [29] 
Gold-thiol 
conjugation 
luciferase HeLa cells > 90% -enzymatic activity [30] 
Covalent binding c-Myc 
HeLa cells 
Hydra 
mouse 
80% -enzymatic activity 
80% -qRT-PCR 
70% -qRT-PCR 
[24,27,31] 
Ionic interaction Lamin A/C HeLa cells 80% -immunoblot [32] 
Gold-thiol 
conjugation 
c-Myc 
LA4-cells 
mouse 
80% -qRT-PCR 
80-90% -bioluminescence 
imaging 
[27] 
Ciclodextrin/ 
adamantin 
interaction 
RRM2 human 
30-70% -qRT-PCR, 
immunolocalization 
[25] 
Mesoporous silica 
NP 
Pore/surface 
adsorption 
GFP/VEGF 
HeLa cells 
MDA-MB-231 
cells 
mouse 
80% -fluorescence intensity 
60% -RT-PCR 
80% -fluorescence intensity 
RT-PCR 
[23] 
Mesoporous silica  
NP  
(+doxorubicin) 
Adsorption 
Pgp (ABC drug 
efflux 
transporter) 
MCF-7 cells 
mouse 
50% - immunoblot 
10-90% -tumor weight, 
immunoblot, qRT-PCR 
[33] 
Gold nanorods-
mesoporous silica 
Covalent binding GFP HeLa cells 
60% -fluorescence intensity 
 
[34] 
Calcium 
Phosphate  NP 
Encapsulation luciferase 
H460 cells 
mouse 
50% enzymatic activity 
50% enzymatic activity 
[20] 
Quantum dots Adsorption 
BACE1  
(b-secretase) 
SK-N-SH cells 50% -immunoblot [35] 
Single walled 
carbon nanotubes 
Covalent binding 
CXCR4  
(cell surface 
co-receptor) 
CD4 
T cells 
peripheral blood 
mononuclear cells 
50%-90% qRT-PCR 
60% qRT-PCR 
[17] 
Table 1
Table 2. Inorganic nanoparticles in clinical trials. 
 
Delivery 
vehicle 
Target 
gene 
Disease Phase Status 
ClinicalTrials.gov 
ID 
Gold + Iron 
Oxide-Silica  
NA 
Coronary Artery Disease 
Atherosclerosis 
1 Completed NCT01436123 
Gold + silica NA 
Stable Angina 
Heart Failure 
Atherosclerosis 
Multivessel Coronary Artery Disease 
1 
2 
Completed NCT01270139 
Gold NA Stomach Diseases 0 Recruiting NCT01420588 
Silica NA 
Head and Neck Cancer 
Melanoma 
Prostate Cancer 
Cervical Cancer 
Uterine Cancer 
0 Recruiting NCT02106598 
Iron oxide 
(magnetic) 
NA Head and Neck Cancer 0 Recruiting NCT01895829 
NA Leukemia - Completed NCT01411904 
NA Brain Neoplasms 1 Completed NCT00769093 
NA Multiple Sclerosis 0 Recruiting NCT01973517 
NA 
Papillary Carcinoma of Thyroid 
Metastatic to Regional Lymph Node 
Metastatic Medullary Thyroid Cancer 
Follicular Thyroid Cancer Lymph 
Node Metastasis 
0 Recruiting NCT01927887 
NA Cancer of Lymph Node 0 Recruiting NCT01815333 
NA 
Myocardial Infarction 
Inflammation 
2 Recruiting NCT01995799 
NA Pancreatic Cancer 4 Recruiting NCT00920023 
NA 
Bladder Cancer 
Genitourinary Cancer 
Prostate Cancer 
- Completed NCT00147238 
NA Myocardial Infarction - Completed NCT01323296 
NA 
Myocardial Infarction 
Inflammation 
- - NCT01127113 
NA Renal Transplant Rejection - Recruiting NCT02006108 
NA: not applicable  
 
Table 2
 Table 3. RNAi-based drugs in clinical trials. Adapted from [14]. 
Delivery 
vehicle 
Target gene Disease Phase Status 
ClinicalTrials.gov 
ID 
Lipid-based 
c-Myc Hepatocellular Carcinoma 
1 
2 
Recruiting NCT02314052 
c-Myc 
Solid Tumors 
Multiple Myeloma 
Non-Hodgkins Lymphoma 
1 Recruiting NCT02110563 
HSP47 
Moderate to Extensive Hepatic 
Fibrosis 
1 Recruiting NCT02227459 
PLK1 
Colorectal, Pancreas, Gastric, 
Breast and Ovarian Cancers 
With Hepatic Metastases 
1 Completed NCT01437007 
EphA2 Advanced Cancers 1 
Not yet 
recruiting 
NCT01591356 
ApoB Hypercholesterolaemia 1 Completed NCT00927459 
VP24, VP35, 
Zaire Ebola 
L-polymerase 
Ebola-virus infection 1 Recruiting NCT01518881 
KSP, VEGF Solid tumors 1 Completed NCT01158079 
TTR 
Transthyretin-mediated 
amyloidosis 
2 Recruiting NCT01617967 
Naked siRNAs 
K6a (N171K 
mutation) 
Pachyonychia congenita 1 Completed NCT00716014 
VEGFR1 
Age-related macular 
degeneration, choroidal 
neovascularization 
2 Completed NCT00395057 
CASP2 
Optic atrophy, non-arteritic 
anterior ischaemic optic 
neuropathy 
1 Completed NCT01064505 
P53 Kidney injury, acute renal failure 1 Completed NCT00554359 
RTP801 
Choroidal neovascularization, 
diabetic retinopathy, diabetic 
macular edema 
2 Completed NCT01445899 
RSV 
nucleocapsid 
Respiratory syncytial virus 
infections 
2 Completed NCT00658086 
bacteria/viral 
vectors 
Conserved 
regions of HBV 
HBV (human hepatitis B virus) 1 Recruiting NCT01872065 
CTNNB1 Familial adenomatous polyposis 
1 
2 
Recruiting - 
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